{"id":"kepivance-palifermin","safety":{"commonSideEffects":[{"rate":null,"effect":"Dysgeusia (taste alteration)"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Hyperamylasemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Palifermin binds to fibroblast growth factor receptor 2 (FGFR2) on epithelial cells, triggering signaling pathways that increase cell proliferation, differentiation, and migration. This accelerates the regeneration and repair of oral mucosa and gastrointestinal epithelium damaged by chemotherapy or radiation, reducing the severity and duration of mucositis.","oneSentence":"Palifermin is a recombinant human fibroblast growth factor 7 (FGF-7) that stimulates epithelial cell proliferation and differentiation to promote healing of damaged mucous membranes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:37.902Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Oral mucositis in patients with hematologic malignancies receiving myeloablative chemotherapy followed by hematopoietic stem cell transplantation"}]},"trialDetails":[{"nctId":"NCT01306019","phase":"PHASE1, PHASE2","title":"Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-09-25","conditions":"X-linked Severe Combined Immunodeficiency (XSCID)","enrollment":40},{"nctId":"NCT06959771","phase":"PHASE1, PHASE2","title":"Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-16","conditions":"CD40L-HyperIgM Syndrome","enrollment":1},{"nctId":"NCT06325709","phase":"PHASE1, PHASE2","title":"Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-17","conditions":"Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease","enrollment":10},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06851767","phase":"PHASE1, PHASE2","title":"Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-05-09","conditions":"X-linked Severe Combined Immunodeficiency, X-SCID, XSCID","enrollment":18},{"nctId":"NCT01746849","phase":"PHASE2","title":"Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Leukemia, Multiple Myeloma, Myelodysplastic Syndrome","enrollment":82},{"nctId":"NCT04177004","phase":"PHASE1","title":"Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-04-30","conditions":"Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":53},{"nctId":"NCT02356159","phase":"PHASE1, PHASE2","title":"Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-24","conditions":"Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","enrollment":34},{"nctId":"NCT05139004","phase":"PHASE1","title":"90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-07-19","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":7},{"nctId":"NCT06986382","phase":"PHASE1, PHASE2","title":"Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2025-07","conditions":"Crohn Disease","enrollment":14},{"nctId":"NCT01085617","phase":"","title":"Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University College, London","startDate":"2010-12","conditions":"Leukemia, Mucositis, Oral Complications","enrollment":""},{"nctId":"NCT01746173","phase":"PHASE2","title":"CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-07","conditions":"T-cell Non-Hodgkin Lymphoma","enrollment":5},{"nctId":"NCT00376935","phase":"PHASE2","title":"Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-12","conditions":"HIV Infections","enrollment":99},{"nctId":"NCT00629798","phase":"PHASE2","title":"Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-02-12","conditions":"Acute Myeloid Leukemia, Advanced Myelodysplastic Syndromes","enrollment":64},{"nctId":"NCT00881556","phase":"EARLY_PHASE1","title":"Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)","status":"TERMINATED","sponsor":"Columbia University","startDate":"2009-08-20","conditions":"Epidermolysis Bullosa","enrollment":3},{"nctId":"NCT01237951","phase":"PHASE2","title":"High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-11-08","conditions":"Myeloma","enrollment":75},{"nctId":"NCT01200329","phase":"PHASE2","title":"High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-06","conditions":"Lymphoma","enrollment":81},{"nctId":"NCT02589145","phase":"PHASE1, PHASE2","title":"Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-06-22","conditions":"Lymphoma","enrollment":8},{"nctId":"NCT03315078","phase":"PHASE1, PHASE2","title":"Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency","status":"UNKNOWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-04","conditions":"X-Linked Combined Immunodeficiency Diseases","enrollment":13},{"nctId":"NCT03042585","phase":"NA","title":"Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHL","status":"COMPLETED","sponsor":"Loyola University","startDate":"2006-06","conditions":"Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma","enrollment":17},{"nctId":"NCT01712945","phase":"PHASE1, PHASE2","title":"Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis","status":"TERMINATED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2012-06","conditions":"Multiple Sclerosis","enrollment":40},{"nctId":"NCT03531281","phase":"PHASE1","title":"Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2018-12-30","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Hematopoietic Cell Transplantation Recipient","enrollment":""},{"nctId":"NCT00728585","phase":"PHASE2","title":"Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant","status":"WITHDRAWN","sponsor":"Children's Oncology Group","startDate":"2008-03-13","conditions":"Gastrointestinal Mucositis, Malignant Neoplasm","enrollment":""},{"nctId":"NCT00593554","phase":"PHASE2","title":"Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies","status":"TERMINATED","sponsor":"Sherif S. Farag","startDate":"2007-08-07","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplasia","enrollment":9},{"nctId":"NCT00360971","phase":"PHASE3","title":"Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer","status":"TERMINATED","sponsor":"Radiation Therapy Oncology Group","startDate":"2006-07","conditions":"Head and Neck Cancer, Mucositis, Pain","enrollment":21},{"nctId":"NCT03100877","phase":"PHASE1, PHASE2","title":"Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2018-01","conditions":"Plasma Cell Leukemia in Remission, Plasma Cell Myeloma","enrollment":""},{"nctId":"NCT02653196","phase":"EARLY_PHASE1","title":"A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2015-09","conditions":"Neuroepithelial Tumor, Solid Tumor, Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":1},{"nctId":"NCT00626639","phase":"PHASE1, PHASE2","title":"A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2005-07","conditions":"Mucositis, Head and Neck Cancer","enrollment":5},{"nctId":"NCT02961816","phase":"PHASE2","title":"Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-06","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT00094861","phase":"PHASE2","title":"Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2005-01","conditions":"Dysphagia, Non-Small Cell Lung Cancer, Lung Cancer","enrollment":100},{"nctId":"NCT00131638","phase":"PHASE3","title":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-01","conditions":"Head and Neck Cancer","enrollment":241},{"nctId":"NCT02037347","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis","status":"TERMINATED","sponsor":"Brett King","startDate":"2010-10","conditions":"Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome","enrollment":1},{"nctId":"NCT01386151","phase":"PHASE2","title":"A Study to Assess Safety and Efficacy of a Novel Treatment, Keratinocyte Growth Factor (KGF), in Asthmatic Patients","status":"COMPLETED","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2009-08","conditions":"Bronchial Asthma","enrollment":24},{"nctId":"NCT00101582","phase":"PHASE3","title":"Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2005-08","conditions":"Mucositis, Solid Tumors, Stomatitis","enrollment":188},{"nctId":"NCT00410982","phase":"PHASE1","title":"Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-12","conditions":"Leukemia, Lymphoma, Myeloma","enrollment":145},{"nctId":"NCT01421173","phase":"PHASE1","title":"Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-08","conditions":"Lymphoma","enrollment":78},{"nctId":"NCT00434161","phase":"PHASE3","title":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2006-12","conditions":"Multiple Myeloma","enrollment":281},{"nctId":"NCT00031148","phase":"PHASE1, PHASE2","title":"Keratinocyte Growth Factor to Prevent Acute GVHD","status":"COMPLETED","sponsor":"FDA Office of Orphan Products Development","startDate":"2001-09","conditions":"Graft-vs-Host Disease","enrollment":72},{"nctId":"NCT00056875","phase":"PHASE1, PHASE2","title":"Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2002-09","conditions":"Graft Versus Host Disease","enrollment":50},{"nctId":"NCT02313792","phase":"PHASE3","title":"Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"The Catholic University of Korea","startDate":"2015-01","conditions":"Mucositis","enrollment":88},{"nctId":"NCT00460421","phase":"PHASE1","title":"A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2006-08","conditions":"Leukemia","enrollment":27},{"nctId":"NCT00361348","phase":"PHASE1","title":"Palifermin DDI (Drug Drug Interaction)","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2005-12","conditions":"Healthy Volunteers","enrollment":45},{"nctId":"NCT01163097","phase":"PHASE1","title":"Study to Characterize the Effect of Heparin on Palifermin Activity","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2010-07","conditions":"Oral Mucositis","enrollment":44},{"nctId":"NCT00352703","phase":"PHASE4","title":"PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2006-04","conditions":"Non-Hodgkin's Lymphoma, Multiple Myeloma","enrollment":145},{"nctId":"NCT00070616","phase":"PHASE1","title":"Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2001-12","conditions":"Leukemia, Lymphoma, Myeloma","enrollment":25},{"nctId":"NCT00189488","phase":"PHASE2","title":"Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2005-12","conditions":"Graft Versus Host Disease, Hematologic Malignancies","enrollment":155},{"nctId":"NCT00109031","phase":"PHASE3","title":"Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2005-01","conditions":"Cancer, Lymphoma, Leukemia","enrollment":47},{"nctId":"NCT00393822","phase":"PHASE2, PHASE3","title":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-08","conditions":"Colon Cancer","enrollment":100},{"nctId":"NCT02114502","phase":"PHASE2","title":"Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-09","conditions":"Myeloma","enrollment":""},{"nctId":"NCT00482846","phase":"PHASE1","title":"Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2007-06","conditions":"Mucositis, Multiple Myeloma","enrollment":38},{"nctId":"NCT01233921","phase":"NA","title":"Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer","status":"COMPLETED","sponsor":"Martin, Paul","startDate":"2010-09","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":6},{"nctId":"NCT00004132","phase":"PHASE2","title":"Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2000-01","conditions":"Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma","enrollment":""},{"nctId":"NCT00004061","phase":"PHASE2","title":"Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1999-05","conditions":"Leukemia, Lymphoma, Oral Complications","enrollment":111},{"nctId":"NCT00041665","phase":"PHASE3","title":"Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Stomatitis","enrollment":""},{"nctId":"NCT00038792","phase":"PHASE1, PHASE2","title":"Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2000-10","conditions":"Acute Graft Versus Host Disease","enrollment":7},{"nctId":"NCT00267046","phase":"PHASE2","title":"Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-12","conditions":"Sarcoma, Oral Mucositis","enrollment":49},{"nctId":"NCT00570999","phase":"PHASE2","title":"Palifermin After Haploidentical PBSCT","status":"WITHDRAWN","sponsor":"European Society for Blood and Marrow Transplantation","startDate":"2008-02","conditions":"Non-Hodgkin's Lymphoma or Hodgkin's Disease, Acute Leukaemia, Myelodysplastic Syndrome","enrollment":""},{"nctId":"NCT00701688","phase":"PHASE1","title":"Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-09","conditions":"Oral Mucositis, Hematopoietic Stem Cell Transplantation","enrollment":19},{"nctId":"NCT00540332","phase":"PHASE1, PHASE2","title":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy","status":"WITHDRAWN","sponsor":"Swedish Orphan Biovitrum","startDate":"2007-10","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT00610818","phase":"","title":"Effect of Palifermin on Skin Tumors in Patients Undergoing Bone Marrow Transplantation","status":"TERMINATED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2007-07","conditions":"Skin Rash","enrollment":7}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":233,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Kepivance (Palifermin)","genericName":"Kepivance (Palifermin)","companyName":"Swedish Orphan Biovitrum","companyId":"swedish-orphan-biovitrum","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Palifermin is a recombinant human fibroblast growth factor 7 (FGF-7) that stimulates epithelial cell proliferation and differentiation to promote healing of damaged mucous membranes. Used for Oral mucositis in patients with hematologic malignancies receiving myeloablative chemotherapy followed by hematopoietic stem cell transplantation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}